| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Frontotemporal Dementia | 14 | 2018 | 55 | 3.71 | Why? |
| Alzheimer Disease | 19 | 2019 | 1020 | 2.67 | Why? |
| Transcranial Magnetic Stimulation | 7 | 2019 | 160 | 1.86 | Why? |
| Cognitive Dysfunction | 12 | 2021 | 1389 | 1.37 | Why? |
| tau Proteins | 5 | 2018 | 162 | 1.19 | Why? |
| Encephalitis | 3 | 2021 | 797 | 1.13 | Why? |
| Amyloid beta-Peptides | 4 | 2018 | 185 | 1.03 | Why? |
| Cognition Disorders | 7 | 2019 | 574 | 1.01 | Why? |
| Migraine Disorders | 2 | 2021 | 530 | 0.99 | Why? |
| Nervous System Diseases | 8 | 2020 | 4092 | 0.94 | Why? |
| Intercellular Signaling Peptides and Proteins | 7 | 2018 | 245 | 0.92 | Why? |
| Cerebral Cortex | 3 | 2019 | 276 | 0.89 | Why? |
| Receptors, AMPA | 2 | 2017 | 17 | 0.88 | Why? |
| Neuropsychological Tests | 13 | 2019 | 954 | 0.84 | Why? |
| Akinetic Mutism | 1 | 2020 | 31 | 0.84 | Why? |
| Serotonergic Neurons | 1 | 2019 | 3 | 0.82 | Why? |
| Tomography, Emission-Computed, Single-Photon | 2 | 2019 | 279 | 0.79 | Why? |
| Lewy Body Disease | 1 | 2019 | 36 | 0.78 | Why? |
| Dopaminergic Neurons | 1 | 2019 | 59 | 0.76 | Why? |
| Muscular Dystrophies | 1 | 2018 | 22 | 0.75 | Why? |
| Frontotemporal Lobar Degeneration | 3 | 2018 | 20 | 0.72 | Why? |
| Neuromuscular Agents | 1 | 2018 | 87 | 0.70 | Why? |
| Paralysis | 1 | 2018 | 92 | 0.70 | Why? |
| Parkinson Disease | 6 | 2019 | 1414 | 0.68 | Why? |
| Copper | 2 | 2018 | 288 | 0.68 | Why? |
| Positron-Emission Tomography | 8 | 2018 | 802 | 0.68 | Why? |
| Acid Ceramidase | 1 | 2016 | 13 | 0.65 | Why? |
| Epilepsies, Myoclonic | 1 | 2016 | 30 | 0.63 | Why? |
| Botulinum Toxins, Type A | 1 | 2018 | 134 | 0.62 | Why? |
| Dermatomyositis | 1 | 2018 | 193 | 0.60 | Why? |
| Muscular Atrophy, Spinal | 1 | 2016 | 68 | 0.60 | Why? |
| Brain | 16 | 2020 | 5133 | 0.60 | Why? |
| Neuroimaging | 3 | 2018 | 1106 | 0.56 | Why? |
| Migraine without Aura | 3 | 2018 | 14 | 0.55 | Why? |
| Mutation, Missense | 3 | 2018 | 863 | 0.55 | Why? |
| Gray Matter | 1 | 2015 | 150 | 0.54 | Why? |
| Migraine with Aura | 3 | 2018 | 33 | 0.53 | Why? |
| Transcranial Direct Current Stimulation | 4 | 2018 | 107 | 0.53 | Why? |
| Glycogen Storage Disease Type II | 1 | 2013 | 26 | 0.53 | Why? |
| Neurodegenerative Diseases | 2 | 2019 | 469 | 0.52 | Why? |
| Magnetic Resonance Imaging | 13 | 2021 | 6551 | 0.50 | Why? |
| Dementia | 7 | 2020 | 1861 | 0.50 | Why? |
| Muscle, Skeletal | 2 | 2021 | 915 | 0.47 | Why? |
| Cholinesterase Inhibitors | 2 | 2018 | 99 | 0.42 | Why? |
| Inpatients | 3 | 2021 | 5161 | 0.40 | Why? |
| Headache Disorders, Primary | 3 | 2019 | 26 | 0.39 | Why? |
| Peptide Fragments | 2 | 2018 | 2075 | 0.39 | Why? |
| Methylprednisolone | 1 | 2020 | 2107 | 0.38 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.38 | Why? |
| Supranuclear Palsy, Progressive | 2 | 2019 | 20 | 0.38 | Why? |
| Phenotype | 6 | 2019 | 4037 | 0.37 | Why? |
| Heredodegenerative Disorders, Nervous System | 1 | 2007 | 1 | 0.36 | Why? |
| Evoked Potentials, Motor | 2 | 2018 | 54 | 0.36 | Why? |
| Long-Term Potentiation | 2 | 2018 | 19 | 0.36 | Why? |
| Vertebral Artery Dissection | 2 | 2018 | 26 | 0.36 | Why? |
| Behavioral Symptoms | 2 | 2018 | 329 | 0.35 | Why? |
| Basal Ganglia Diseases | 1 | 2007 | 16 | 0.35 | Why? |
| Amyloid | 2 | 2019 | 156 | 0.35 | Why? |
| Vasospasm, Intracranial | 2 | 2019 | 50 | 0.35 | Why? |
| Cerebral Hemorrhage | 4 | 2020 | 820 | 0.35 | Why? |
| Case-Control Studies | 14 | 2020 | 17671 | 0.34 | Why? |
| Neural Pathways | 2 | 2019 | 155 | 0.33 | Why? |
| Ataxia | 2 | 2018 | 133 | 0.33 | Why? |
| Cerebellum | 2 | 2018 | 119 | 0.33 | Why? |
| Age of Onset | 4 | 2017 | 557 | 0.32 | Why? |
| Italy | 25 | 2021 | 38444 | 0.31 | Why? |
| Heterozygote | 5 | 2017 | 249 | 0.31 | Why? |
| Stroke | 9 | 2021 | 8839 | 0.31 | Why? |
| Sleep Wake Disorders | 1 | 2017 | 1463 | 0.30 | Why? |
| Affect | 2 | 2018 | 549 | 0.30 | Why? |
| Aged | 60 | 2021 | 215776 | 0.29 | Why? |
| Sleep | 1 | 2017 | 2695 | 0.27 | Why? |
| Female | 75 | 2021 | 380317 | 0.27 | Why? |
| Male | 71 | 2021 | 367725 | 0.27 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.27 | Why? |
| Humans | 110 | 2021 | 930598 | 0.27 | Why? |
| Magnetic Resonance Angiography | 4 | 2018 | 282 | 0.26 | Why? |
| Brain Ischemia | 4 | 2021 | 2813 | 0.26 | Why? |
| Autoimmune Diseases | 1 | 2017 | 1996 | 0.26 | Why? |
| Mutation | 10 | 2018 | 12376 | 0.25 | Why? |
| Radiopharmaceuticals | 2 | 2019 | 763 | 0.25 | Why? |
| Middle Aged | 55 | 2021 | 270681 | 0.25 | Why? |
| Substantia Nigra | 2 | 2019 | 22 | 0.25 | Why? |
| Geriatric Assessment | 4 | 2021 | 1372 | 0.24 | Why? |
| Biomarkers | 8 | 2018 | 23361 | 0.24 | Why? |
| Amyotrophic Lateral Sclerosis | 2 | 2018 | 398 | 0.24 | Why? |
| Atrophy | 3 | 2018 | 192 | 0.23 | Why? |
| Tissue Plasminogen Activator | 2 | 2019 | 778 | 0.23 | Why? |
| Glial Fibrillary Acidic Protein | 1 | 2021 | 138 | 0.23 | Why? |
| Neural Inhibition | 2 | 2018 | 19 | 0.23 | Why? |
| Thalamus | 2 | 2019 | 75 | 0.23 | Why? |
| Psychiatric Status Rating Scales | 3 | 2018 | 1340 | 0.23 | Why? |
| Hippocampus | 3 | 2018 | 237 | 0.22 | Why? |
| Aphasia, Primary Progressive | 2 | 2017 | 8 | 0.22 | Why? |
| Mental Status and Dementia Tests | 2 | 2018 | 208 | 0.21 | Why? |
| Chlamydophila pneumoniae | 1 | 2021 | 98 | 0.21 | Why? |
| beta 2-Microglobulin | 1 | 2020 | 102 | 0.21 | Why? |
| Speech Disorders | 1 | 2020 | 55 | 0.21 | Why? |
| Electromyography | 2 | 2019 | 278 | 0.21 | Why? |
| Genetic Association Studies | 3 | 2018 | 559 | 0.21 | Why? |
| Autoimmunity | 2 | 2018 | 841 | 0.20 | Why? |
| Aged, 80 and over | 23 | 2021 | 88759 | 0.20 | Why? |
| Tropanes | 1 | 2019 | 18 | 0.20 | Why? |
| Fluorine Radioisotopes | 1 | 2019 | 59 | 0.20 | Why? |
| REM Sleep Behavior Disorder | 1 | 2019 | 24 | 0.20 | Why? |
| Receptor, Notch3 | 1 | 2018 | 4 | 0.20 | Why? |
| Theory of Mind | 1 | 2018 | 10 | 0.20 | Why? |
| Rivastigmine | 1 | 2018 | 6 | 0.19 | Why? |
| Prosopagnosia | 1 | 2018 | 3 | 0.19 | Why? |
| T-Cell Intracellular Antigen-1 | 1 | 2018 | 5 | 0.19 | Why? |
| Amyloid beta-Protein Precursor | 1 | 1998 | 30 | 0.19 | Why? |
| Prefrontal Cortex | 2 | 2018 | 151 | 0.19 | Why? |
| Lewy Bodies | 1 | 2018 | 3 | 0.19 | Why? |
| Temporal Lobe | 2 | 2018 | 83 | 0.19 | Why? |
| Synapsins | 1 | 2018 | 9 | 0.19 | Why? |
| CADASIL | 1 | 2018 | 22 | 0.19 | Why? |
| Carotid Artery Injuries | 1 | 2018 | 19 | 0.19 | Why? |
| Activities of Daily Living | 1 | 2007 | 1530 | 0.19 | Why? |
| Hypotension, Orthostatic | 1 | 2019 | 55 | 0.19 | Why? |
| Hydrocephalus, Normal Pressure | 1 | 2018 | 16 | 0.19 | Why? |
| NAV1.4 Voltage-Gated Sodium Channel | 1 | 2017 | 2 | 0.18 | Why? |
| Myotonia | 1 | 2017 | 2 | 0.18 | Why? |
| Mitochondrial Diseases | 1 | 2019 | 62 | 0.18 | Why? |
| Sarcoglycans | 1 | 2017 | 2 | 0.18 | Why? |
| Myokymia | 1 | 2017 | 1 | 0.18 | Why? |
| Kv1.1 Potassium Channel | 1 | 2017 | 2 | 0.18 | Why? |
| Cerebral Infarction | 2 | 2018 | 245 | 0.18 | Why? |
| Spinocerebellar Ataxias | 1 | 2017 | 20 | 0.18 | Why? |
| Frontal Lobe | 2 | 2018 | 191 | 0.18 | Why? |
| Electroencephalography | 3 | 2021 | 1242 | 0.18 | Why? |
| Intracranial Arterial Diseases | 1 | 2017 | 9 | 0.18 | Why? |
| Chloride Channels | 1 | 2017 | 51 | 0.18 | Why? |
| Remission, Spontaneous | 1 | 2018 | 186 | 0.18 | Why? |
| Tension-Type Headache | 1 | 2017 | 28 | 0.18 | Why? |
| Neuronal Plasticity | 1 | 2018 | 98 | 0.17 | Why? |
| alpha-Synuclein | 1 | 2018 | 71 | 0.17 | Why? |
| Pneumonia, Mycoplasma | 1 | 2021 | 292 | 0.17 | Why? |
| Gait Disorders, Neurologic | 1 | 2018 | 64 | 0.17 | Why? |
| Joint Instability | 1 | 2017 | 20 | 0.17 | Why? |
| Adaptor Proteins, Vesicular Transport | 1 | 2018 | 88 | 0.17 | Why? |
| Dystonic Disorders | 1 | 2017 | 19 | 0.17 | Why? |
| Guillain-Barre Syndrome | 2 | 2021 | 1495 | 0.17 | Why? |
| Diffusion Magnetic Resonance Imaging | 2 | 2017 | 317 | 0.17 | Why? |
| Statistics, Nonparametric | 2 | 2018 | 1008 | 0.17 | Why? |
| Niemann-Pick Disease, Type C | 1 | 2017 | 17 | 0.17 | Why? |
| Leukoaraiosis | 1 | 2016 | 18 | 0.17 | Why? |
| Validation Studies as Topic | 1 | 2017 | 121 | 0.17 | Why? |
| Pituitary Neoplasms | 1 | 2019 | 130 | 0.17 | Why? |
| Facial Recognition | 1 | 2018 | 75 | 0.17 | Why? |
| Voice | 1 | 2018 | 75 | 0.17 | Why? |
| ATP-Binding Cassette Transporters | 1 | 2017 | 48 | 0.17 | Why? |
| Vascular Malformations | 1 | 2017 | 52 | 0.16 | Why? |
| Connectome | 1 | 2017 | 67 | 0.16 | Why? |
| Skin Diseases, Genetic | 1 | 2017 | 65 | 0.16 | Why? |
| Spinal Cord | 1 | 2018 | 281 | 0.16 | Why? |
| Cloud Computing | 1 | 2019 | 214 | 0.16 | Why? |
| Telemetry | 1 | 2019 | 240 | 0.16 | Why? |
| Docosahexaenoic Acids | 1 | 2017 | 145 | 0.15 | Why? |
| Perfusion Imaging | 1 | 2018 | 199 | 0.15 | Why? |
| Ultrasonography, Doppler, Transcranial | 1 | 2017 | 143 | 0.15 | Why? |
| Fluorodeoxyglucose F18 | 3 | 2018 | 1153 | 0.15 | Why? |
| Prodromal Symptoms | 1 | 2016 | 133 | 0.15 | Why? |
| Language | 2 | 2018 | 655 | 0.15 | Why? |
| Autoantibodies | 2 | 2017 | 2094 | 0.15 | Why? |
| Sleep Arousal Disorders | 1 | 2014 | 3 | 0.15 | Why? |
| Analysis of Variance | 2 | 2018 | 950 | 0.15 | Why? |
| Puerperal Disorders | 1 | 2017 | 151 | 0.15 | Why? |
| Early Diagnosis | 3 | 2017 | 2443 | 0.15 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.15 | Why? |
| Homozygote | 1 | 2016 | 230 | 0.14 | Why? |
| Pneumonia, Viral | 11 | 2020 | 243684 | 0.14 | Why? |
| Siblings | 1 | 2016 | 226 | 0.14 | Why? |
| Arteries | 1 | 2017 | 283 | 0.14 | Why? |
| Social Perception | 1 | 2018 | 371 | 0.14 | Why? |
| Image Interpretation, Computer-Assisted | 2 | 2019 | 665 | 0.14 | Why? |
| Treatment Outcome | 13 | 2021 | 51732 | 0.14 | Why? |
| Fibrinogen | 1 | 2020 | 1048 | 0.14 | Why? |
| Coronavirus Infections | 11 | 2020 | 253789 | 0.14 | Why? |
| Habits | 1 | 2017 | 334 | 0.14 | Why? |
| Autoantigens | 1 | 2017 | 388 | 0.14 | Why? |
| Cognitive Reserve | 1 | 2013 | 17 | 0.14 | Why? |
| DNA-Binding Proteins | 1 | 2017 | 469 | 0.14 | Why? |
| Interleukin-8 | 1 | 2020 | 964 | 0.13 | Why? |
| Alanine Transaminase | 1 | 2020 | 1329 | 0.13 | Why? |
| Aging | 1 | 2010 | 3581 | 0.13 | Why? |
| Aspartate Aminotransferases | 1 | 2020 | 1394 | 0.13 | Why? |
| Warfarin | 1 | 2018 | 402 | 0.13 | Why? |
| Thrombectomy | 3 | 2021 | 2272 | 0.13 | Why? |
| Functional Neuroimaging | 1 | 2013 | 86 | 0.12 | Why? |
| Aneurysm, Dissecting | 1 | 2018 | 303 | 0.12 | Why? |
| Myalgia | 1 | 2019 | 1015 | 0.12 | Why? |
| Rare Diseases | 1 | 2017 | 373 | 0.12 | Why? |
| Health Services for the Aged | 1 | 2020 | 602 | 0.12 | Why? |
| Risk-Taking | 1 | 2017 | 508 | 0.12 | Why? |
| User-Computer Interface | 1 | 2019 | 1068 | 0.12 | Why? |
| Retrospective Studies | 17 | 2021 | 105322 | 0.12 | Why? |
| Adult | 27 | 2021 | 244371 | 0.12 | Why? |
| Disease Progression | 5 | 2020 | 13580 | 0.12 | Why? |
| Psychometrics | 1 | 2019 | 1269 | 0.11 | Why? |
| Empathy | 1 | 2018 | 658 | 0.11 | Why? |
| Self Report | 3 | 2019 | 3802 | 0.11 | Why? |
| Amnesia | 1 | 2010 | 18 | 0.11 | Why? |
| Neurons | 1 | 2017 | 864 | 0.11 | Why? |
| Thrombolytic Therapy | 2 | 2021 | 2218 | 0.11 | Why? |
| Independent Living | 1 | 2017 | 842 | 0.11 | Why? |
| Advisory Committees | 1 | 2018 | 1418 | 0.10 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.10 | Why? |
| Blood Platelets | 2 | 2018 | 1704 | 0.10 | Why? |
| Postpartum Period | 1 | 2017 | 936 | 0.10 | Why? |
| Psychomotor Performance | 1 | 2010 | 110 | 0.10 | Why? |
| Arterial Occlusive Diseases | 1 | 2014 | 363 | 0.10 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2020 | 2483 | 0.10 | Why? |
| Models, Neurological | 1 | 2009 | 121 | 0.10 | Why? |
| Betacoronavirus | 11 | 2020 | 204454 | 0.10 | Why? |
| Olfaction Disorders | 2 | 2021 | 3704 | 0.10 | Why? |
| Neurology | 1 | 2021 | 1613 | 0.10 | Why? |
| Alcohol Drinking | 2 | 2018 | 1663 | 0.10 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 1458 | 0.10 | Why? |
| Patient Care Management | 1 | 2020 | 1514 | 0.09 | Why? |
| Syndrome | 2 | 2019 | 1310 | 0.09 | Why? |
| Brain Diseases | 1 | 2020 | 1463 | 0.09 | Why? |
| Insulin | 1 | 2017 | 1316 | 0.09 | Why? |
| Health Facilities | 1 | 2016 | 1230 | 0.09 | Why? |
| Prospective Studies | 10 | 2021 | 43301 | 0.09 | Why? |
| Double-Blind Method | 5 | 2018 | 5988 | 0.09 | Why? |
| Severity of Illness Index | 9 | 2021 | 48226 | 0.09 | Why? |
| Frail Elderly | 1 | 2017 | 1427 | 0.09 | Why? |
| Fibrinolytic Agents | 1 | 2019 | 1702 | 0.09 | Why? |
| Quality Improvement | 1 | 2020 | 2435 | 0.09 | Why? |
| Comorbidity | 3 | 2021 | 34796 | 0.08 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.08 | Why? |
| Health Status | 1 | 2020 | 3259 | 0.08 | Why? |
| Executive Function | 2 | 2018 | 173 | 0.08 | Why? |
| International Cooperation | 1 | 2020 | 3436 | 0.08 | Why? |
| Risk Assessment | 3 | 2020 | 25439 | 0.08 | Why? |
| Pedigree | 2 | 2017 | 502 | 0.08 | Why? |
| Longitudinal Studies | 4 | 2021 | 9893 | 0.08 | Why? |
| Diagnosis, Differential | 2 | 2017 | 7220 | 0.08 | Why? |
| Follow-Up Studies | 4 | 2018 | 17020 | 0.07 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.07 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.07 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Dietary Supplements | 1 | 2017 | 2251 | 0.07 | Why? |
| Random Allocation | 1 | 2007 | 773 | 0.07 | Why? |
| Cells, Cultured | 1 | 2016 | 5835 | 0.07 | Why? |
| Chronic Disease | 2 | 2018 | 5139 | 0.07 | Why? |
| Hospitalization | 5 | 2021 | 54280 | 0.07 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.07 | Why? |
| Life Style | 1 | 2017 | 2708 | 0.07 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.07 | Why? |
| Genetic Variation | 1 | 2018 | 3919 | 0.06 | Why? |
| Cohort Studies | 5 | 2021 | 36005 | 0.06 | Why? |
| Reproducibility of Results | 4 | 2021 | 11304 | 0.06 | Why? |
| Adolescent | 6 | 2020 | 86841 | 0.06 | Why? |
| Pandemics | 14 | 2021 | 389249 | 0.06 | Why? |
| Memory Disorders | 2 | 2013 | 190 | 0.06 | Why? |
| Decision Making | 1 | 2017 | 3132 | 0.06 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.06 | Why? |
| Hospital Mortality | 3 | 2021 | 22087 | 0.06 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.06 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.06 | Why? |
| Electrophysiological Phenomena | 1 | 2021 | 59 | 0.06 | Why? |
| Sensory Receptor Cells | 1 | 2021 | 44 | 0.06 | Why? |
| Motor Neurons | 1 | 2021 | 52 | 0.06 | Why? |
| Quality of Life | 2 | 2019 | 9820 | 0.06 | Why? |
| Registries | 2 | 2021 | 12327 | 0.05 | Why? |
| Morbidity | 1 | 2007 | 1426 | 0.05 | Why? |
| Cognition | 3 | 2018 | 1394 | 0.05 | Why? |
| Coinfection | 1 | 2021 | 6820 | 0.05 | Why? |
| Medical Oncology | 1 | 2017 | 3826 | 0.05 | Why? |
| Bromocriptine | 1 | 2000 | 42 | 0.05 | Why? |
| Ethylene Glycols | 1 | 2019 | 7 | 0.05 | Why? |
| Aphasia | 1 | 2000 | 33 | 0.05 | Why? |
| Electrodiagnosis | 1 | 2021 | 152 | 0.05 | Why? |
| Dopamine Agonists | 1 | 2000 | 61 | 0.05 | Why? |
| Multiple Chronic Conditions | 1 | 2020 | 115 | 0.05 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.05 | Why? |
| Isomerism | 1 | 1998 | 13 | 0.05 | Why? |
| Stroke, Lacunar | 1 | 2018 | 20 | 0.05 | Why? |
| Neural Conduction | 1 | 2021 | 261 | 0.05 | Why? |
| Psychological Techniques | 1 | 2018 | 40 | 0.05 | Why? |
| Action Potentials | 1 | 2021 | 368 | 0.05 | Why? |
| Radioactive Tracers | 1 | 2018 | 9 | 0.05 | Why? |
| Mycoplasma pneumoniae | 1 | 2021 | 233 | 0.05 | Why? |
| Reaction Time | 1 | 2018 | 96 | 0.05 | Why? |
| Aniline Compounds | 1 | 2019 | 120 | 0.05 | Why? |
| Reperfusion | 1 | 2021 | 491 | 0.05 | Why? |
| Cerebrospinal Fluid Shunts | 1 | 2018 | 34 | 0.05 | Why? |
| Young Adult | 6 | 2020 | 93724 | 0.05 | Why? |
| Transdermal Patch | 1 | 2018 | 52 | 0.05 | Why? |
| Benzothiazoles | 1 | 2019 | 128 | 0.05 | Why? |
| Image Processing, Computer-Assisted | 2 | 2018 | 1383 | 0.05 | Why? |
| Ataxins | 1 | 2017 | 2 | 0.05 | Why? |
| Risk Factors | 8 | 2021 | 71621 | 0.05 | Why? |
| Electromagnetic Fields | 1 | 2018 | 34 | 0.05 | Why? |
| Putamen | 1 | 2018 | 24 | 0.05 | Why? |
| Ceruloplasmin | 1 | 2017 | 12 | 0.05 | Why? |
| Time | 1 | 2021 | 631 | 0.05 | Why? |
| Resistin | 1 | 2018 | 16 | 0.05 | Why? |
| Ghrelin | 1 | 2018 | 22 | 0.05 | Why? |
| Nicotinamide Phosphoribosyltransferase | 1 | 2018 | 30 | 0.05 | Why? |
| Electrophoresis, Polyacrylamide Gel | 1 | 1998 | 238 | 0.05 | Why? |
| Speech Therapy | 1 | 2000 | 152 | 0.05 | Why? |
| Language Disorders | 1 | 1998 | 29 | 0.05 | Why? |
| Postural Balance | 1 | 2019 | 144 | 0.04 | Why? |
| Motor Cortex | 1 | 2018 | 71 | 0.04 | Why? |
| RNA-Directed DNA Polymerase | 1 | 1998 | 170 | 0.04 | Why? |
| Ultrafiltration | 1 | 2017 | 42 | 0.04 | Why? |
| Neurologic Examination | 1 | 2021 | 428 | 0.04 | Why? |
| Ion Channel Gating | 1 | 2017 | 22 | 0.04 | Why? |
| C-Peptide | 1 | 2018 | 77 | 0.04 | Why? |
| Stilbenes | 1 | 2019 | 113 | 0.04 | Why? |
| COS Cells | 1 | 2017 | 157 | 0.04 | Why? |
| Basal Ganglia | 1 | 2017 | 49 | 0.04 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.04 | Why? |
| Gait | 1 | 2018 | 137 | 0.04 | Why? |
| Famous Persons | 1 | 2018 | 74 | 0.04 | Why? |
| Dopamine | 1 | 2018 | 123 | 0.04 | Why? |
| Endovascular Procedures | 2 | 2018 | 1302 | 0.04 | Why? |
| Embryo, Mammalian | 1 | 2017 | 86 | 0.04 | Why? |
| Platelet Aggregation Inhibitors | 2 | 2018 | 1671 | 0.04 | Why? |
| Anesthesia, Epidural | 1 | 2017 | 92 | 0.04 | Why? |
| Mental Competency | 1 | 2018 | 128 | 0.04 | Why? |
| Pregnancy | 2 | 2017 | 23879 | 0.04 | Why? |
| C9orf72 Protein | 1 | 2016 | 27 | 0.04 | Why? |
| Anticoagulants | 1 | 2018 | 9563 | 0.04 | Why? |
| Amyloidosis | 1 | 2018 | 178 | 0.04 | Why? |
| Depression | 2 | 2018 | 14116 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Coffee | 1 | 2017 | 79 | 0.04 | Why? |
| Blotting, Western | 1 | 1998 | 863 | 0.04 | Why? |
| Nerve Net | 1 | 2017 | 118 | 0.04 | Why? |
| Posture | 1 | 2017 | 199 | 0.04 | Why? |
| Myoclonus | 1 | 2017 | 133 | 0.04 | Why? |
| Primary Cell Culture | 1 | 2017 | 501 | 0.04 | Why? |
| Thrombosis | 1 | 2018 | 7504 | 0.04 | Why? |
| Comprehension | 1 | 2018 | 259 | 0.04 | Why? |
| Time Factors | 3 | 2018 | 31397 | 0.04 | Why? |
| Administration, Intravenous | 1 | 2019 | 1115 | 0.04 | Why? |
| Cross-Over Studies | 1 | 2018 | 867 | 0.04 | Why? |
| Drug Substitution | 1 | 2018 | 385 | 0.04 | Why? |
| Patient Selection | 1 | 2009 | 4560 | 0.04 | Why? |
| White Matter | 1 | 2018 | 369 | 0.04 | Why? |
| Semantics | 1 | 1995 | 104 | 0.04 | Why? |
| Drainage | 1 | 2018 | 414 | 0.04 | Why? |
| Tomography, X-Ray Computed | 2 | 2020 | 25144 | 0.03 | Why? |
| Quarantine | 1 | 2021 | 18418 | 0.03 | Why? |
| Ischemic Attack, Transient | 1 | 2018 | 439 | 0.03 | Why? |
| GTPase-Activating Proteins | 1 | 2013 | 36 | 0.03 | Why? |
| Genetic Testing | 1 | 2017 | 395 | 0.03 | Why? |
| Anesthesia, Obstetrical | 1 | 2017 | 230 | 0.03 | Why? |
| Gene Frequency | 1 | 2018 | 1210 | 0.03 | Why? |
| Multimodal Imaging | 1 | 2017 | 534 | 0.03 | Why? |
| Olfactory Perception | 1 | 2013 | 93 | 0.03 | Why? |
| Prevalence | 3 | 2021 | 25773 | 0.03 | Why? |
| Sensitivity and Specificity | 3 | 2018 | 22971 | 0.03 | Why? |
| Mice, Knockout | 1 | 2018 | 1815 | 0.03 | Why? |
| Europe | 2 | 2021 | 12702 | 0.03 | Why? |
| Single-Blind Method | 1 | 2016 | 1283 | 0.03 | Why? |
| Mental Disorders | 1 | 2015 | 6742 | 0.03 | Why? |
| Induced Pluripotent Stem Cells | 1 | 2017 | 584 | 0.03 | Why? |
| Brain Mapping | 1 | 2013 | 228 | 0.03 | Why? |
| Sensory Thresholds | 1 | 2013 | 115 | 0.03 | Why? |
| RNA, Messenger | 2 | 2013 | 5131 | 0.03 | Why? |
| Belgium | 1 | 2018 | 2064 | 0.03 | Why? |
| Odorants | 1 | 2013 | 219 | 0.03 | Why? |
| Polymerase Chain Reaction | 2 | 2013 | 6740 | 0.03 | Why? |
| Cell Differentiation | 1 | 2017 | 1338 | 0.03 | Why? |
| Pre-Eclampsia | 1 | 2017 | 599 | 0.03 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.03 | Why? |
| Prognosis | 3 | 2021 | 32490 | 0.03 | Why? |
| Treatment Failure | 1 | 2016 | 2106 | 0.03 | Why? |
| Sex Factors | 2 | 2018 | 11014 | 0.03 | Why? |
| History, 20th Century | 1 | 2016 | 1282 | 0.03 | Why? |
| Aspirin | 1 | 2018 | 1043 | 0.02 | Why? |
| Rats | 1 | 2017 | 2764 | 0.02 | Why? |
| History, 21st Century | 1 | 2016 | 1849 | 0.02 | Why? |
| Musculoskeletal Diseases | 1 | 2016 | 646 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.02 | Why? |
| Recovery of Function | 1 | 2019 | 2461 | 0.02 | Why? |
| Animals | 5 | 2018 | 78931 | 0.02 | Why? |
| Proteins | 1 | 2016 | 921 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2018 | 4260 | 0.02 | Why? |
| Critical Care | 2 | 2021 | 14081 | 0.02 | Why? |
| Incidence | 2 | 2020 | 25622 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| Gene Expression | 1 | 2017 | 3332 | 0.02 | Why? |
| Leukocytes | 1 | 2013 | 1046 | 0.02 | Why? |
| Cardiology | 1 | 2021 | 2873 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2016 | 5440 | 0.02 | Why? |
| Risk | 1 | 2018 | 5288 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2018 | 6543 | 0.02 | Why? |
| Binding Sites | 1 | 2018 | 6201 | 0.02 | Why? |
| Neurosurgical Procedures | 1 | 2016 | 1738 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Protein Domains | 1 | 2018 | 6563 | 0.02 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.02 | Why? |
| Time-to-Treatment | 1 | 2021 | 5883 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| HEK293 Cells | 1 | 2017 | 8394 | 0.02 | Why? |
| Atrial Fibrillation | 1 | 2018 | 2320 | 0.02 | Why? |
| Smoking | 1 | 2017 | 3358 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2013 | 3788 | 0.01 | Why? |
| Logistic Models | 1 | 2016 | 9089 | 0.01 | Why? |
| Protein Binding | 1 | 2018 | 11430 | 0.01 | Why? |
| Mortality | 1 | 2018 | 7132 | 0.01 | Why? |
| Models, Statistical | 1 | 2018 | 5312 | 0.01 | Why? |
| Respiratory Insufficiency | 1 | 2021 | 7301 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.01 | Why? |
| Reference Values | 1 | 1998 | 795 | 0.01 | Why? |
| Child, Preschool | 1 | 2019 | 36283 | 0.01 | Why? |
| Stress, Psychological | 1 | 2017 | 10231 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.01 | Why? |
| Child | 1 | 2019 | 70012 | 0.01 | Why? |